New Manufacturing Platform at Hsinchu Operational

GE Healthcare has completed installation of its FlexFactory™ biomanufacturing platform at JHL Biotech’s Research Centre and manufacturing plant in Hsinchu, Taiwan.  The new GMP compliant manufacturing platform is similar to that of the production process at JHL Biotech’s KUBio modular biopharmaceutical factory currently under construction by GE Healthcare at the Biolake Science Park in Wuhan, China.

JHL Biotech’s FlexFactory in Taiwan will be used for cell line development, process development, and cGMP manufacturing in pre-clinical and early-stage clinical work.  In addition, it will serve as a proving ground for JHL Biotech for technology transfer. GE Healthcare’s experienced Shanghai Fast Trak team will validate equipment at the site and will train local JHL Biotech staff.

Olivier Loeillot, General Manager affordable to more people by utilising innovations such as FlexFactory.  Our biomanufacturing capability increases with the installation of cGMP manufacturing in our Taiwan facility. Because our biomanufacturing capabilities are shared across our facilities in Asia, we give our partners a unique offering.”

Racho Jordanov, Co-founder, President and CEO of JHL Biotech, added, “JHL Biotech will make world-class biopharmaceuticals of Enterprise Solutions, GE Healthcare Life Sciences, commented, “Our offering of tools, technologies and services for biomanufacturing has strength in both breadth and depth.  For JHL Biotech we have been able to take an approach which recognises the differing requirements of multiple sites, whilst at the same time allowing them to replicate processes. FlexFactory is highly complementary to our KUBio offering, primarily aimed at those organisations repurposing or expanding an existing site.”